. Author manuscript; available in PMC: 2021 Oct 1.

Published in final edited form as: Lancet Haematol. 2020 Oct;7(10):e715–e723. doi: 10.1016/S2352-3026(20)30294-5

Table 3:

Post-HCT one-year cause-specific mortality in relation to donor IFNL4 genotype in the DBMT set

Primary cause of death	NCI validation set^a N=348		DBMT independent set N=1245		Combined DBMT sets N=1953
	N^b events	HR^b (95% CI)	N^b events	HR^c (95% CI) p-value	HR (95% CI) p-value
GvHD	20	2.0 (1.05–3.84) P=0.03	78	1.40 (1.02–1.92) P=0.04	1.46 (1.11–1.94) 0.008
Infections	14	1.49 (0.71–3.10) 0.29	80	1.54 (1.13–2.1) 0.006	1.54 (1.16–2.04) P=0.003
Organ failure	13	1.80 (0.83–3.91) P=0.14	86	0.91 (0.65–1.26) 0.57	1.05 (0.78–1.40) P=0.74
Relapse	52	0.89 (0.58–1.37) P=0.60	313	0.97 (0.82–1.14) P=0.68	0.96 (0.82–1.12) P=0.60

^a.

Patients with adjudicated causes of death data generated as part of the DBMT study were included in this analysis

^b.

Number of events and at risk by genotype is available in Supplemental Appendix p 9

^c.

Cause-specific hazards accounting for competing mortality of causes other than those under study. HRs are calculated based on additive genetic models in relation to IFNL4 genotype (rs12979860-T allele; risk allele) and adjusted for donor and recipient age, GvHD prophylaxis, use of total body irradiation, and stratified by graft type.